Suvi Linna-Kuosmanen

Suvi Linna-Kuosmanen is a senior scientist at the A.I. Virtanen Institute and a principal investigator and leader of Linna Lab. The lab was established in October 2023 and is currently located at the University of Eastern Finland.

Linna-Kuosmanen uses single-cell and spatial omics, data integration, and machine learning / AI models to identify novel drug targets and biomarkers for clinical applications and more personalized medicine. Her ongoing work combines unique human patient samples and engineered human tissue models with state-of-the-art experimental and computational methods, to elucidate disease mechanisms of major aging-related chronic diseases, as well as aging itself, with special emphasis on coronary artery disease, heart failure, and atrial fibrillation. In addition to mapping molecular changes in clinical samples, she investigates the effects of environmental exposures, such as micro- and nanoplastics, in the cardiac cell and tissue environments to estimate their impact on disease manifestation and progression.

Prior to her current position, Linna-Kuosmanen trained as a postdoctoral researcher mapping cardiovascular disease-associated changes in the cells of ex vivo human heart samples, and establishing high-resolution maps of microvasculature in these clinical samples at the Computer Science and Artificial Intelligence Lab (CSAIL) of Massachusetts Institute of Technology (MIT) and the Broad Institute of MIT and Harvard, Cambridge, USA. She received her PhD in molecular medicine at the University of Eastern Finland, Kuopio, Finland, where she examined the disease mechanisms and putative biomarkers of atherosclerosis through cardiovascular genomics. Linna-Kuosmanen holds a masters in biochemistry from the University of Kuopio, Finland, and studied neuroscience in honours program at the University of Glasgow during her bachelors stage.